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BALB/c mice infected with human metapneumovirus (hMPV) were treated with the sulfated sialyl
lipid NMSO3 (one dose of 50 mg kg
”1) given at the time of infection. NMSO3 significantly
reduced viral replication in the lungs, as well as hMPV-induced body weight loss, pulmonary
inflammation and cytokine production, suggesting that antiviral treatment initiated at the beginning
of viral infection can modify hMPV-induced disease.
Human metapneumovirus (hMPV) is a recently identified
human respiratory viral pathogen belonging to the family
Paramyxoviridae (van den Hoogen et al., 2001). hMPV is
associated with upper and lower respiratory tract infections
in children and adults, as reported in studies worldwide.
According to various reports, between 5 and 12% of all
respiratory tract infections in younger infants are caused by
hMPV, second only to respiratory syncytial virus (RSV),
and it may account for 10% of all hospitalizations of
elderly patients with respiratory tract infections (reviewed
by Hamelin & Boivin, 2005). No specific antivirals or other
therapeutic agents are licensed to treat hMPV infection.
Similarly, no vaccine is currently available. We and others
have recently identified BALB/c mice as an effective murine
model to investigate hMPV-induced airway disease
(Alvarez et al., 2004; Guerrero-Plata et al., 2005; Hamelin
et al., 2005). Ribavirin, a nucleoside analogue of guanosine
used in the treatment of RSV infection, has recently been
shown to affect hMPV replication in vitro and in vivo
(Hamelin et al., 2006; Wyde et al., 2003). Similarly,
NMSO3, a sulfated sialyl lipid with potent antiviral activity
against RSV, has recently been shown to inhibit hMPV
replication in vitro (Wyde et al., 2004). In this study, we
assessed the effect of NMSO3 treatment on hMPV
replication and pulmonary inflammation in vivo, using a
BALB/c model of infection.
Female BALB/c mice (Harlan Sprague Dawley), 6–7 weeks
old, were housed under pathogen-free conditions. A total
of four experimental groups consisting of two treatment
groups (carrier and NMSO3) for each infection group
(mock- and hMPV-infected) was used for all experiments.
For each experiment, four to five mice were used per
group. Experiments were repeated two to three times.
There was no effect of the vehicle by itself; therefore, the
groups of mock-infected+carrier and hMPV-infected+
carrier are identified in the text and figures as mock- and
hMPV-infected. Under light anaesthesia, mice were
inoculated intranasally (i.n.) with 1610
7 TCID50 hMPV
in a total volume of 50 ml. This volume of inoculum has
been shown to deliver the virus directly to the lungs. At 30–
60 min after viral inoculation, mice were administered
NMSO3 i.n. at a concentration of 10, 50 or 100 mg kg
21 in
a total volume of 50 ml. NMSO3 was prepared in water at a
stock concentration of 100 mg ml
21 and then diluted in
PBS to the final desired concentration immediately before
administration. Mice were weighed daily from day 0 to 10
post-infection (p.i.). At days 1 and 4 p.i., mice were
sacrificed to determine lung viral titres and cellular
inflammation, and to measure cytokine and chemokine
production, as described previously (Guerrero-Plata et al.,
2005, 2006; Haeberle et al., 2001).
To determine the effects of NMSO3 on hMPV infection,
we initially examined whether NMSO3 altered hMPV
replication in vivo. We tested three different concentrations
of NMSO3, given on the first day of hMPV infection, based
on a previous study that used NMSO3 in a rat model of
RSV infection, showing amelioration of RSV-induced
clinical illness (Kimura et al., 2000). In our mouse model
of hMPV infection, increased viral titres could be detected
as early as day 3 p.i., with peak viral titres occurring at day
5 p.i. and viral clearance by day 7 p.i. (data not shown).
NMSO3 administration of 10 mg kg
21 only marginally
reduced hMPV replication from 4.5±0.1 to 4.1±0.05
log10, whilst treatment with 50 mg kg
21 significantly
decreased peak viral load by about 1 log, from
5.12±0.31 to 4.1±0.32 log10. Administration of
100 mg kg
21 resulted in a further reduction in viral
replication (5.2±0.1 to 3.9±0.2 log10), but was also
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body weight, an important parameter of hMPV-induced
clinical illness (see below), in the animals infected and
treated with NMSO3 compared with the animals infected
with virus alone.
Mice infected with 1610
7 TCID50 hMPV lost 5–10% of
their original body weight, with a peak that occurred
between days 1 and 2 p.i. They gradually returned to their
original weight and then started to lose weight again for an
additional 4–5 days before returning to baseline levels.
Mock-infected mice did not loose weight (data not shown).
HMPV-infected mice treated with NMSO3 showed a
similar body weight loss in the first 3 days of infection;
however, they did not loose additional weight after
returning to baseline levels, as shown in Fig. 1(a).
We then tested the efficacy of 50 mg NMSO3 kg
21 given at
1 day p.i. NMSO3 treatment was still effective in reducing
viral replication, although not as well as administration
immediately after infection (reduction of ~0.6 log vs 1 log
in viral titres). Mice infected with hMPV and treated with
NMSO3 the day after infection showed a body weight loss
similar to the untreated infected mice, but seemed to
recover faster than the untreated mice, as shown in Fig.
1(b). As administering 50 mg NMSO3 kg
21 at the time of
infection seemed to be the most effective treatment in
modulating hMPV-induced clinical disease, all subsequent
experiments were performed using this treatment protocol.
To determine whether NMSO3 altered hMPV-induced
lung inflammation, total and differential cell counts in
bronchoalveolar lavages (BALs) were measured. In mock-
infected mice, total lung cell count was between 1610
4 and
1.5610
4, with macrophages representing the majority of
the cell population. We observed a significant attenuation
of total cellular influx following NMSO3 treatment in
HMPV-infected mice on day 1 p.i. (P50.056), with a
similar trend at day 4 p.i. (Fig. 2a). HMPV infection
induces a significant recruitment of neutrophils to the lung
within the first 3 days of infection, whilst mononuclear
cells, including macrophages/monocytes and lymphocytes,
start to increase at day 3 p.i., representing the majority of
the lung inflammatory cells from day 5 p.i. (Kolli et al.,
2008). NMSO3 administration did not cause significant
changes in the distribution of the inflammatory cell
population at day 1 p.i. between treated and untreated
groups, whilst there was a significant increase in neutrophil
recruitment in the airways by day 4 p.i. (Fig. 2b).
HMPV infection of BALB/c mice results in significant
production of cytokines and chemokines (Alvarez et al.,
2004; Guerrero-Plata et al., 2005; Hamelin et al., 2005),
which are likely to play a major role in pulmonary
inflammation. Therefore, we determined whether NMSO3
Fig. 1. Effect of NMSO3 administration on hMPV-induced body
weight loss. Mice were treated with 50 mg NMSO3 kg
”1 at the
time of hMPV infection (a) or at 24 h p.i. (b). The results show a
representative diagram from three different experiments. All data
points represent the means±SD of four to five animals.
Fig. 2. Effect of NMSO3 on airway inflammation. (a) The total
number of cells was measured in the BAL of hMPV-infected mice,
either untreated or treated with NMSO3, at days 1 and 4 p.i. Data
are expressed as means±SD and are representative of three
different experiments. (b) Differential cell count was measured in
BALs of hMPV-infected mice, untreated or treated with NMSO3, at
days 1 and 4 p.i. *, P,0.01 relative to hMPV-infected mice.
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chemokine secretion by analysing their levels in BAL
samples collected at days 1 and 4 p.i. As shown in Fig. 3(a),
NMSO3 treatment significantly reduced the level of the
chemokine RANTES, a potent chemoattractant of mono-
nuclear cells, while increasing the amount of KC, a
chemokine important for neutrophil recruitment. The
pro-inflammatory cytokines interleukin (IL)-1a, IL-1b, IL-
6 and tumour necrosis factor alpha were strongly
upregulated in the lungs of infected animals at day 1 p.i.,
and NMSO3 treatment significantly reduced all four
cytokine protein levels (Fig. 3b). These cytokines were no
longer detectable in the BALs of infected mice at day 4 p.i.
In contrast, granulocyte colony-stimulating factor (G-CSF)
and gamma interferon (IFN-c) were secreted in significant
amounts at day 4 p.i., and were significantly reduced in
hMPV-infected animals treated with NMSO3 (Fig. 3c).
Our study demonstrates that a single administration of
NMSO3, at the time of hMPV infection, is effective in
reducing viral replication, clinical illness, pulmonary
inflammation and chemokine/cytokine production. The
initial in vitro study suggested that NMSO3 was most
effective when present at the beginning of hMPV
replication, possibly affecting viral attachment and inter-
nalization (Wyde et al., 2004). For this reason, we decided
to treat the mice concurrently with hMPV infection. A
single dose of 50 mg NMSO3 kg
21 was highly effective in
preventing significant body weight loss, suggesting that
antiviral treatment can have a significant impact on
hMPV-induced disease, as also shown recently by the use
of ribavirin in a similar model of hMPV infection
(Hamelin et al., 2006), in particular when administered
at the beginning of infection. NMSO3 given 24 h after
infection resulted in only a marginal improvement in
hMPV-induced illness, as assessed by body weight loss.
This result was similar to what we have shown previously
with antioxidant treatment in the context of RSV infection,
which was effective if given before or at the moment of
Fig. 3. Effect of NMSO3 on cytokine and
chemokine release in BAL. Cytokine and
chemokine production were measured using
a Bioplex array in the BAL of mock- and hMPV-
infected mice, either untreated or treated with
NMSO3, at days 1 (a, b) and 4 (c) p.i. Data are
expressed as means±SD and are represent-
ative of three different experiments. *, P,0.01
relative to hMPV-infected mice.
NMSO3 in hMPV infection
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clinical disease administered 1 day after infection, when
clinical disease and lung inflammation are already present
(Castro et al., 2006). This finding suggests that early
therapeutic intervention may be necessary to improve clinical
outcome in both hMPV and RSV infections. In future studies,
it would be important toassess other important parameters of
clinical illness such as airway hyper-responsiveness, which has
been reported in BALB/c mice infected with hMPV or with
other paramyxoviruses such as RSV. Similarly, alternative
methods of administration, for example via aerosolization,
could be tested for efficacy. HMPV infection of BALB/c mice
induces a significant lung inflammatory response, with
recruitment of phagocytes and then mononuclear cells to
the airways, concomitant with the induction of chemokines
and cytokines. The role of the inflammatory response in
hMPV-induced clinical illness has not yet been investigated.
However, the recent finding of a significant reduction of body
weight loss following glucocorticoid treatment (Hamelin et
al., 2006) in a similar mouse model of hMPV infection
suggests that modulating pulmonary inflammation would be
beneficial in hMPV-induced disease. A recent in vitro study
has shown that NMSO3 reduces RSV-induced chemokine
production (Miller et al., 2004). Similarly, our results showed
that NMSO3 treatment significantly reduced hMPV-induced
chemokine/cytokine production, paralleled by a reduction in
pulmonaryinflammation.Theonlyexceptionwassecretionof
KC, a neutrophil chemoattractant, which explains the
relatively higher proportion of these phagocytic cells at day
4 p.i. in the NMSO3-treated group. Although this beneficial
effect is probably due to the reduction in hMPV replication, it
is possible that, in addition to its antiviral activity, NMSO3
may also possess general anti-inflammatory properties, as
recently shown in vitro by inhibition of adhesion-dependent
leukocyte activation (Shodai et al., 2003). We have recently
shown that CD4
+ T lymphocytes play an important role in
modulating hMPV-induced clinical illness and pulmonary
inflammation (Kolli et al., 2008). It is possible that NMSO3
treatment modulation of the innate response also modified
theadaptiveimmuneresponse,leadingtoabeneficialeffecton
disease that is not due only tothe antiviralmechanism.Future
studies should address whether NMSO3 modifies recruit-
ment/maturation of dendritic cells and whether there are
changes in the phenotype of T cells.
In summary, NMSO3 treatment improved several aspects
of hMPV-induced disease and should be considered for
further evaluation in other animal models.
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